EGFR Gene Mutation clinical trials at UCSF
1 research study open to eligible people

• Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

  open to eligible people ages 18 years and up

  This is a phase I/Ib, open-label, single-center, single-arm study of alisertib and osimertinib for patients with stage IV EGFR-mutated lung cancer, incorporating both a dose escalation and dose-expansion phase

  San Francisco, California

Last updated: September 10, 2019